{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T07:51:42Z","timestamp":1773906702330,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T00:00:00Z","timestamp":1664928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"QIAGEN"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The World Health Organisation (WHO) recommends that testing and treatment for latent tuberculosis infection (LTBI) should be undertaken in high-risk groups using either interferon gamma release assays (IGRAs) or a\u00a0tuberculin skin test\u00a0(TST). As IGRAs are more expensive than TST, an assessment of the cost-effectiveness of IGRAs can guide decision makers on the most appropriate choice of test for different high-risk populations. This current review aimed to provide the most up to date evidence on the cost-effectiveness evidence on LTBI testing in high-risk groups\u2014specifically evidence reporting the costs per QALY of different testing strategies.\n<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A comprehensive search of databases including MEDLINE, EMBASE and NHS-EED was undertaken from 2011 up to March 2021. Studies were screened and extracted by two independent reviewers. The study quality was assessed using the Bias in Economic Evaluation Checklist (ECOBIAS). A narrative synthesis of the included studies was undertaken.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty-two studies reported in thirty-three documents were included in this review. Quality of included studies was generally high, although there was a weakness across all studies referencing sources correctly and\/or justifying choices of parameter values chosen or assumptions where parameter values were not available. Inclusions of IGRAs in testing strategies was consistently found across studies to be cost-effective but this result was sensitive to underlying LTBI prevalence rates.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>While some concerns remain about uncertainty in parameter values used across included studies, the evidence base since 2010 has grown with modelling approaches addressing the weakness pointed out in previous reviews but still reaching the same conclusion that IGRAs are likely to be cost-effective in high-income countries for high-risk populations. Evidence is also required on the cost-effectiveness of different strategies in low to middle income countries and countries with high TB burden.\n<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12890-022-02149-x","type":"journal-article","created":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T08:02:53Z","timestamp":1664956973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["A systematic review of cost-utility analyses of screening methods in latent tuberculosis infection in high-risk populations"],"prefix":"10.1186","volume":"22","author":[{"given":"James","family":"Mahon","sequence":"first","affiliation":[]},{"given":"Sophie","family":"Beale","sequence":"additional","affiliation":[]},{"given":"Hayden","family":"Holmes","sequence":"additional","affiliation":[]},{"given":"Mick","family":"Arber","sequence":"additional","affiliation":[]},{"given":"Vladyslav","family":"Nikolayevskyy","sequence":"additional","affiliation":[]},{"given":"Riccardo","family":"Alagna","sequence":"additional","affiliation":[]},{"given":"Davide","family":"Manissero","sequence":"additional","affiliation":[]},{"given":"David","family":"Dowdy","sequence":"additional","affiliation":[]},{"given":"Giovanni Battista","family":"Migliori","sequence":"additional","affiliation":[]},{"given":"Giovanni","family":"Sotgiu","sequence":"additional","affiliation":[]},{"given":"Raquel","family":"Duarte","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,10,5]]},"reference":[{"key":"2149_CR1","volume-title":"WHO consolidated guidelines on tuberculosis","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. WHO consolidated guidelines on tuberculosis. Geneva: World Health Organization; 2020."},{"issue":"4","key":"2149_CR2","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1183\/09031936.00214014","volume":"45","author":"K L\u00f6nnroth","year":"2015","unstructured":"L\u00f6nnroth K, Migliori GB, Abubakar I, D\u2019Ambrosio L, de Vries G, Diel R, et al. Towards tuberculosis elimination: an action framework for low-incidence countries. Eur Respir J. 2015;45(4):928\u201352.","journal-title":"Eur Respir J."},{"key":"2149_CR3","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/1472-6963-11-247","volume":"11","author":"A Nienhaus","year":"2011","unstructured":"Nienhaus A, Schablon A, Costa JT, Diel R. Systematic review of cost and cost-effectiveness of different TB-screening strategies. BMC Health Serv Res. 2011;11:247.","journal-title":"BMC Health Serv Res."},{"key":"2149_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.tube.2016.04.007","volume":"99","author":"P Auguste","year":"2016","unstructured":"Auguste P, Tsertsvadze A, Court R, Pink J. A systematic review of economic models used to assess the cost-effectiveness of strategies for identifying latent tuberculosis in high-risk groups. Tuberculosis. 2016;99:81\u201391.","journal-title":"Tuberculosis."},{"issue":"9","key":"2149_CR5","doi-asserted-by":"publisher","first-page":"965","DOI":"10.5588\/ijtld.16.0935","volume":"21","author":"D Zenner","year":"2017","unstructured":"Zenner D, Hafezi H, Potter J, Capone S, Matteelli A. Effectiveness and cost-effectiveness of screening migrants for active tuberculosis and latent tuberculous infection. Int J Tuberc Lung Dis. 2017;21(9):965\u201376.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"2","key":"2149_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jval.2015.11.006","volume":"19","author":"M Koufopoulou","year":"2016","unstructured":"Koufopoulou M, Sutton AJ, Breheny K, Diwakar L. Methods used in economic evaluations of tuberculin skin tests and interferon gamma release assays for the screening of latent tuberculosis infection: a systematic review. Value Health. 2016;19(2):267\u201376.","journal-title":"Value Health."},{"issue":"4","key":"2149_CR7","first-page":"513","volume":"16","author":"CC Adarkwah","year":"2016","unstructured":"Adarkwah CC, van Gils PF, Hiligsmann M, Evers SMAA. Risk of bias in model-based economic evaluations: the ECOBIAS checklist. Expert Rev Pharm Out. 2016;16(4):513\u201323.","journal-title":"Expert Rev Pharm Out."},{"issue":"5","key":"2149_CR8","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1164\/rccm.201101-0181OC","volume":"184","author":"BP Linas","year":"2011","unstructured":"Linas BP, Wong AY, Freedberg KA, Horsburgh CR Jr. Priorities for screening and treatment of latent tuberculosis infection in the United States. Am J Respir Crit Care Med. 2011;184(5):590\u2013601.","journal-title":"Am J Respir Crit Care Med."},{"key":"2149_CR9","doi-asserted-by":"crossref","unstructured":"Linas BP, Wong AY, Freedberg KA, Horsburgh CR (2011) The cost effectiveness of tuberculin skin test and interferon gamma release assay screening for latent tuberculosis infection in the U.S. Am J Respir Crit Care Med. 2011;183(1 MeetingAbstracts)","DOI":"10.1164\/ajrccm-conference.2011.183.1_MeetingAbstracts.A6337"},{"issue":"12","key":"2149_CR10","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1001\/jamainternmed.2017.3941","volume":"177","author":"A Tasillo","year":"2017","unstructured":"Tasillo A, Salomon JA, Trikalinos TA, Horsburgh CR Jr, Marks SM, Linas BP. Cost-effectiveness of testing and treatment for latent tuberculosis infection in residents born outside the united states with and without medical comorbidities in a simulation model. JAMA Intern Med. 2017;177(12):1755\u201364.","journal-title":"JAMA Intern Med."},{"key":"2149_CR11","first-page":"25","volume":"25","author":"Y Jo","year":"2020","unstructured":"Jo Y, Shrestha S, Gomes I, Marks S, Hill A, Asay G, et al. Model-based cost-effectiveness of state-level latent tuberculosis interventions in California, Florida, New York and Texas. Clin Infect Dis. 2020;25:25.","journal-title":"Clin Infect Dis."},{"issue":"4","key":"2149_CR12","doi-asserted-by":"publisher","first-page":"e0214532","DOI":"10.1371\/journal.pone.0214532","volume":"14","author":"AJ Goodell","year":"2019","unstructured":"Goodell AJ, Shete PB, Vreman R, McCabe D, Porco TC, Barry PM, et al. Outlook for tuberculosis elimination in California: an individual-based stochastic model. PLoS ONE. 2019;14(4):e0214532.","journal-title":"PLoS ONE."},{"issue":"10","key":"2149_CR13","doi-asserted-by":"publisher","first-page":"e0186778","DOI":"10.1371\/journal.pone.0186778","volume":"12","author":"JR Campbell","year":"2017","unstructured":"Campbell JR, Johnston JC, Sadatsafavi M, Cook VJ, Elwood RK, Marra F. Cost-effectiveness of post-landing latent tuberculosis infection control strategies in new migrants to Canada. PLoS ONE. 2017;12(10):e0186778.","journal-title":"PLoS ONE."},{"issue":"4","key":"2149_CR14","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3201\/eid2504.171630","volume":"25","author":"JR Campbell","year":"2019","unstructured":"Campbell JR, Johnston JC, Cook VJ, Sadatsafavi M, Elwood RK, Marra F. Cost-effectiveness of latent tuberculosis infection screening before immigration to low-incidence countries. Emerg Infect Dis. 2019;25(4):661\u201371.","journal-title":"Emerg Infect Dis."},{"issue":"1","key":"2149_CR15","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1053\/j.ajkd.2018.07.014","volume":"73","author":"JR Campbell","year":"2019","unstructured":"Campbell JR, Johnston JC, Ronald LA, Sadatsafavi M, Balshaw RF, Cook VJ, et al. Screening for latent tuberculosis infection in migrants with CKD: a cost-effectiveness analysis. Am J Kidney Dis. 2019;73(1):39\u201350.","journal-title":"Am J Kidney Dis."},{"issue":"38","key":"2149_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta20380","volume":"20","author":"P Auguste","year":"2016","unstructured":"Auguste P, Tsertsvadze A, Pink J, Court R, Seedat F, Gurung T, et al. Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation. Health Technol Assess. 2016;20(38):1\u2013678.","journal-title":"Health Technol Assess."},{"issue":"56","key":"2149_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta22560","volume":"22","author":"I Abubakar","year":"2018","unstructured":"Abubakar I, Lalvani A, Southern J, Sitch A, Jackson C, Onyimadu O, et al. Two interferon gamma release assays for predicting active tuberculosis: the UK PREDICT TB prognostic test study. Health Technol Assess. 2018;22(56):1\u201396.","journal-title":"Health Technol Assess."},{"issue":"5","key":"2149_CR18","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.tmaid.2016.05.010","volume":"14","author":"A Kowada","year":"2016","unstructured":"Kowada A. Cost effectiveness of interferon-gamma release assay for tuberculosis screening using three months of rifapentine and isoniazid among long-term expatriates from low to high incidence countries. Travel Med Infect Dis. 2016;14(5):489\u201398.","journal-title":"Travel Med Infect Dis."},{"issue":"1","key":"2149_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jinf.2013.08.009","volume":"68","author":"A Kowada","year":"2014","unstructured":"Kowada A. Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries. J Infect. 2014;68(1):32\u201342.","journal-title":"J Infect."},{"key":"2149_CR20","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.ijid.2020.03.010","volume":"92S","author":"S Al Abri","year":"2020","unstructured":"Al Abri S, Kowada A, Yaqoubi F, Al Khalili S, Ndunda N, Petersen E. Cost-effectiveness of IGRA\/QFT-Plus for TB screening of migrants in Oman. Int J Infect Dis. 2020;92S:S72\u20137.","journal-title":"Int J Infect Dis."},{"issue":"2","key":"2149_CR21","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jhin.2014.10.002","volume":"89","author":"A Kowada","year":"2015","unstructured":"Kowada A, Takasaki J, Kobayashi N. Cost-effectiveness of interferon-gamma release assay for systematic tuberculosis screening of healthcare workers in low-incidence countries. J Hosp Infect. 2015;89(2):99\u2013108.","journal-title":"J Hosp Infect."},{"issue":"SUPPL. 1","key":"2149_CR22","first-page":"44","volume":"13","author":"S Capocci","year":"2012","unstructured":"Capocci S, Smith C, Morris S, Bhagani S, Cropley I, Johnson M, et al. Is testing for latent tuberculosis infection in an UK HIV clinic cost effective? HIV Med. 2012;13(SUPPL. 1):44.","journal-title":"HIV Med."},{"issue":"SUPPL. 2","key":"2149_CR23","doi-asserted-by":"publisher","first-page":"A32","DOI":"10.1136\/thoraxjnl-2014-206260.64","volume":"69","author":"SJ Capocci","year":"2014","unstructured":"Capocci SJ, Sewell J, Smith C, Cropley I, Bhagani S, Morris S, et al. Prospective health economic evaluation of different recommended strategies for TB testing in a contemporary HIV positive cohort. Thorax. 2014;69(SUPPL. 2):A32.","journal-title":"Thorax."},{"issue":"1","key":"2149_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1183\/09031936.00067114","volume":"46","author":"S Capocci","year":"2015","unstructured":"Capocci S, Smith C, Morris S, Bhagani S, Cropley I, Abubakar I, et al. Decreasing cost effectiveness of testing for latent TB in HIV in a low TB incidence area. Eur Respir J. 2015;46(1):165\u201374.","journal-title":"Eur Respir J."},{"issue":"Suppl 1","key":"2149_CR25","first-page":"38","volume":"17","author":"S Capocci","year":"2016","unstructured":"Capocci S, Sewell J, Smith C, Cropley I, Bhagani S, Morris S, et al. Testing for TB in a contemporary UK HIV clinic-is it really worth it? HIV Med. 2016;17(Suppl 1):38\u20139.","journal-title":"HIV Med."},{"issue":"Suppl 3","key":"2149_CR26","doi-asserted-by":"publisher","first-page":"A50","DOI":"10.1136\/thoraxjnl-2016-209333.94","volume":"71","author":"S Capocci","year":"2016","unstructured":"Capocci S, Sewell J, Smith C, Cropley I, Bhagani S, Solamalai A, et al. Neither UK tuberculosis infection testing guideline appears cost-effective in a contemporary hiv infected population. Thorax. 2016;71(Suppl 3):A50\u20131.","journal-title":"Thorax."},{"issue":"2","key":"2149_CR27","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jinf.2020.05.055","volume":"81","author":"SJ Capocci","year":"2020","unstructured":"Capocci SJ, Sewell J, Smith C, Cropley I, Bhagani S, Solamalai A, et al. Cost effectiveness of testing HIV infected individuals for TB in a low TB\/HIV setting. J Infect. 2020;81(2):289\u201396.","journal-title":"J Infect."},{"issue":"10","key":"2149_CR28","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1017\/S0950268812002907","volume":"141","author":"A Kowada","year":"2013","unstructured":"Kowada A. Cost-effectiveness of interferon-gamma release assay for entry tuberculosis screening in prisons. Epidemiol Infect. 2013;141(10):2224\u201334.","journal-title":"Epidemiol Infect."},{"issue":"15","key":"2149_CR29","doi-asserted-by":"publisher","first-page":"3215","DOI":"10.1017\/S0950268816001382","volume":"144","author":"A Kowada","year":"2016","unstructured":"Kowada A. Cost-effectiveness of interferon-gamma release assays for tuberculosis screening in nursing homes. Epidemiol Infect. 2016;144(15):3215\u201325.","journal-title":"Epidemiol Infect."},{"issue":"Suppl 3","key":"2149_CR30","first-page":"A174","volume":"72","author":"M Hayama","year":"2017","unstructured":"Hayama M, Green N, Seneviratne SL, O\u2019Donoghue M, Drey N, Kon OM. Latent tuberculosis infection screening of adult close contacts in London: A cost-utility analysis. Thorax. 2017;72(Suppl 3):A174.","journal-title":"Thorax."},{"issue":"7","key":"2149_CR31","doi-asserted-by":"publisher","first-page":"857","DOI":"10.5588\/ijtld.14.0518","volume":"19","author":"A Kowada","year":"2015","unstructured":"Kowada A. Cost-effectiveness of tobacco cessation support combined with tuberculosis screening among contacts who smoke. Int J Tuberc Lung Dis. 2015;19(7):857\u201363.","journal-title":"Int J Tuberc Lung Dis."},{"issue":"1","key":"2149_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.jinf.2018.07.003","volume":"78","author":"A Kowada","year":"2019","unstructured":"Kowada A. Interferon-gamma release assay for tuberculosis screening of solid-organ transplant recipients is cost-effective. J Infect. 2019;78(1):58\u201365.","journal-title":"J Infect."},{"issue":"1","key":"2149_CR33","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1053\/j.ajkd.2012.06.004","volume":"61","author":"BL Laskin","year":"2013","unstructured":"Laskin BL, Goebel J, Starke JR, Schauer DP, Eckman MH. Cost-effectiveness of latent tuberculosis screening before steroid therapy for idiopathic nephrotic syndrome in children. Am J Kidney Dis. 2013;61(1):22\u201332.","journal-title":"Am J Kidney Dis."},{"issue":"3","key":"2149_CR34","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1007\/s10620-013-2820-9","volume":"59","author":"M van der Have","year":"2014","unstructured":"van der Have M, Oldenburg B, Fidder HH, Belderbos TD, Siersema PD, van Oijen MG. Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-alpha inhibitors in Crohn\u2019s disease. Dig Dis Sci. 2014;59(3):554\u201363.","journal-title":"Dig Dis Sci."},{"issue":"2","key":"2149_CR35","doi-asserted-by":"publisher","first-page":"e000630","DOI":"10.1136\/bmjopen-2011-000630","volume":"2","author":"MN Eralp","year":"2012","unstructured":"Eralp MN, Scholtes S, Martell G, Winter R, Exley AR. Screening of healthcare workers for tuberculosis: development and validation of a new health economic model to inform practice. BMJ Open. 2012;2(2):e000630.","journal-title":"BMJ Open."},{"issue":"2","key":"2149_CR36","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jhin.2011.01.026","volume":"78","author":"A Kowada","year":"2011","unstructured":"Kowada A, Deshpande GA, Takahashi O, Shimbo T, Fukui T. Cost-effectiveness analysis of interferon-gamma release assays versus chest X-ray for annual tuberculosis screening of healthcare workers. J Hosp Infect. 2011;78(2):152\u20134.","journal-title":"J Hosp Infect."},{"issue":"3","key":"2149_CR37","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1017\/ice.2018.334","volume":"40","author":"ME Png","year":"2019","unstructured":"Png ME, Yoong J, Ong CWM, Fisher D, Bagdasarian N. A screening strategy for latent tuberculosis in healthcare workers: Cost-effectiveness and budget impact of universal versus targeted screening. Infect Control Hosp Epidemiol. 2019;40(3):341\u20139.","journal-title":"Infect Control Hosp Epidemiol."},{"issue":"7","key":"2149_CR38","doi-asserted-by":"publisher","first-page":"A859","DOI":"10.1016\/j.jval.2016.08.432","volume":"19","author":"A Kowada","year":"2016","unstructured":"Kowada A. Cost-effectiveness of interferon-gamma release assay for tuberculosis screening of mental patients with tobacco smoking. Value Health. 2016;19(7):A859.","journal-title":"Value Health."},{"issue":"1","key":"2149_CR39","doi-asserted-by":"publisher","first-page":"e0189531","DOI":"10.1371\/journal.pone.0189531","volume":"13","author":"J Li","year":"2018","unstructured":"Li J, Yip BHK, Leung C, Chung W, Kwok KO, Chan EYY, et al. Screening for latent and active tuberculosis infection in the elderly at admission to residential care homes: a cost-effectiveness analysis in an intermediate disease burden area. PLoS ONE. 2018;13(1):e0189531.","journal-title":"PLoS ONE."},{"issue":"3","key":"2149_CR40","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF03262207","volume":"16","author":"A Kowada","year":"2012","unstructured":"Kowada A. Cost effectiveness of interferon-gamma release assay for school-based tuberculosis screening. Mol Diagn Ther. 2012;16(3):181\u201390.","journal-title":"Mol Diagn Ther."},{"issue":"4","key":"2149_CR41","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1378\/chest.09-2350","volume":"137","author":"R Diel","year":"2010","unstructured":"Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest. 2010;137(4):952\u201368.","journal-title":"Chest."},{"issue":"1","key":"2149_CR42","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1183\/09031936.00115110","volume":"37","author":"R Diel","year":"2011","unstructured":"Diel R, Goletti D, Ferrara G, Bothamley G, Cirillo D, et al. Interferon-\u03b3 release assays for the diagnosis of latent Mycobacterium tuberculosis infection: a systematic review and meta-analysis. Eur Respir J. 2011;37(1):88\u201399.","journal-title":"Eur Respir J."}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-02149-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-022-02149-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-022-02149-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,5]],"date-time":"2022-10-05T09:08:33Z","timestamp":1664960913000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-022-02149-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,5]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2149"],"URL":"https:\/\/doi.org\/10.1186\/s12890-022-02149-x","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,5]]},"assertion":[{"value":"28 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors give consent for the publication of identifiable details, which can include photograph(s) and\/or videos and\/or case history and\/or details within the text (\u201cMaterial\u201d) to be published in the above Journal and Article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JM, SB, HH and MA received funding from QIAGEN for the review. VN, RA, DM are employees of QIAGEN. DD, GBM, GS, RD attended QIAGEN funded advisory boards for the research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"375"}}